Processing

Please wait...

Settings

Settings

Goto Application

1. WO1996007423 - IMMUNOMODULATING MEDICINAL AGENT

Publication Number WO/1996/007423
Publication Date 14.03.1996
International Application No. PCT/RU1995/000079
International Filing Date 27.04.1995
Chapter 2 Demand Filed 27.09.1996
IPC
A61K 9/127 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
10Dispersions; Emulsions
127Liposomes
A61K 31/435 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
A61K 31/473 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
47Quinolines; Isoquinolines
473ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
CPC
A61K 31/435
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
A61K 31/473
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
47Quinolines; Isoquinolines
473ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
A61K 9/127
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
10Dispersions; Emulsions
127Liposomes
A61P 37/02
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
37Drugs for immunological or allergic disorders
02Immunomodulators
Applicants
  • TRAVKIN, Oleg Viktorovich [RU]/[RU]
  • GENKIN, Dmitry Dmitrievich [RU]/[RU]
Inventors
  • TRAVKIN, Oleg Viktorovich
  • GENKIN, Dmitry Dmitrievich
Agents
  • PEIZNER, Ben Abovich
Priority Data
9510374023.03.1995RU
Publication Language Russian (RU)
Filing Language Russian (RU)
Designated States
Title
(EN) IMMUNOMODULATING MEDICINAL AGENT
(FR) SUBSTANCE PHARMACEUTIQUE IMMUNOMODULATRICE
Abstract
(EN)
The invention relates to medicine and veterinary science, specifically to immunomodulating medicinal preparations based on hydrophobic interferon inducers used in anti-viral therapy. The problem addressed by the invention is to broaden the range of effective uses, improve potency, reduce toxicity and simplify production of the agent in question. A novelty is the use of complex ethers of 10-methylene carboxy-9-acridone as a low molecular weight interferon inducer in conjunction with a pharmaceutically acceptable carrier, and the selection of substances used to ensure solubility in water and for microencapsulation in the case of a lipid carrier.
(FR)
L'invention concerne les sciences médicales et vétérinaires, plus spécifiquement des préparations pharmaceutiques immunomodulatrices basées sur inducteurs hydrophobes d'interféron utilisés en thérapie antivirale. L'objet de l'invention est d'élargir le domaine d'utilisation efficace de cette substance pharmaceutique, d'en accroître l'efficacité, d'en réduire la toxicité et d'en simplifier la production. La nouveauté réside dans l'utilisation d'éthers complexes de 10-méthylène carboxy-9-acridone comme inducteur à faible poids moléculaire d'interféron avec un porteur pharmaceutiquement acceptable, et dans le choix de substances assurant sa solubilité dans l'eau et pour la microencapsulation en cas de porteur lipidique.
Also published as
Latest bibliographic data on file with the International Bureau